Department of Medical Genetics, Haseki Training and Research Hospital, Health Sciences University, Fatih/Istanbul, Turkey.
Biochem Genet. 2024 Dec;62(6):5144-5156. doi: 10.1007/s10528-024-10880-9. Epub 2024 Jul 7.
Polycystic kidney disease (PKD) is a common inherited disease characterized by multiple cysts in kidneys and various extra renal manifestations. Molecular diagnosis plays a crucial role in confirming both the clinical diagnosis and preimplantation genetic diagnosis furthermore, selecting appropriate treatment options. This study aimed to expand the understanding of genetic mutations in patients with polycystic kidney disease and to improve the management of patients. The study included 92 patients with a clinical diagnosis of PKD based on renal ultrasound criteria. Targeted next-generation sequencing was performed using a custom panel kit. Of the 92 patients included in the study, pathogenic/likely pathogenic variants of the PKD1, PKD2 genes were detected in 37 patients (40.2%), while 8 patients (8.6%) had variants with uncertain clinical significance. After the additional assessment of pathogenic/likely pathogenic variants, it was found that 15 of the variants in PKD1 and 2 of the variants in PKD2 have not been reported in the literature previously. Additionally, pathogenic variants, 5 of which were novel, have been identified in different genes in 8 patients. This study presented the largest patient cohort conducted in Turkey. These findings were significant in expanding our understanding of the genetic variations associated with polycystic kidney disease. The study contrıbuted the literature data on polycystic kidney disease by reporting important findings that could pave the way for further investigations in the diagnosis, treatment, and management of the affected patients.
多囊肾病(PKD)是一种常见的遗传性疾病,其特征是肾脏内有多个囊肿和各种肾脏外表现。分子诊断在确认临床诊断和植入前遗传诊断方面起着至关重要的作用,并且还可以选择适当的治疗方案。本研究旨在扩展对多囊肾病患者遗传突变的认识,并改善患者的管理。该研究纳入了 92 名根据肾脏超声标准临床诊断为 PKD 的患者。使用定制的下一代测序试剂盒对这些患者进行了靶向下一代测序。在纳入研究的 92 名患者中,在 37 名患者(40.2%)中检测到 PKD1、PKD2 基因的致病性/可能致病性变异,而 8 名患者(8.6%)的变异具有不确定的临床意义。在对致病性/可能致病性变异进行额外评估后,发现 PKD1 中的 15 个变异和 PKD2 中的 2 个变异以前在文献中没有报道过。此外,在 8 名患者的不同基因中还发现了 8 个具有致病性变异,其中 5 个是新的。本研究是在土耳其进行的最大的患者队列研究。这些发现对于扩展我们对与多囊肾病相关的遗传变异的理解具有重要意义。该研究通过报告可能为受影响患者的诊断、治疗和管理提供进一步研究方向的重要发现,为多囊肾病的文献数据做出了贡献。